Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression
This article was originally published in The Pink Sheet Daily
Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.
You may also be interested in...
Obese patients who are severely ill with a high BMI and co-morbidities, and who are highly motivated to try a new therapy and willing to pay for it out-of-pocket, will be targeted for Saxenda.
In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.
Timing of the study to be discussed at Dec. 7 advisory committee meeting.